The key aspects of the patented technology are precise and non-invasive treatment of dermis and epidermis using therapeutic ultrasound guided in real-time by an optical system during treatment.

The United States Patent and Trademark Office (USPTO) granted TOOsonix A/S patents regarding its key high-intensity focused ultrasound (HIFU) technologies for dermatology The U.S. patent and already granted patents in Europe and China to complete the first phase of securing intellectual property rights for TOOsonix’s unique technology in the major jurisdictions.

The key aspects of the patented technology are precise and non-invasive treatment of dermis and epidermis using therapeutic ultrasound guided in real-time by an optical system during treatment, which enhances both safety and efficacy for patients.

The technology has been implemented in the company’s first product – TOOsonix System ONE-M, which is currently in the late phase of approvals for medical treatments. Through series of recently published clinical case-studies, it has been demonstrated that the system provides superior results in various dermatological conditions, such as actinic keratosis, basal cell carcinoma, condylomas, vascular malformations, seborrheic keratosis, Kaposi’s sarcoma and many other conditions originating in the epidermis and dermis of the human skin. Clinical studies on treatment of basal cell carcinoma and cutaneous neurofibroma are on-going.

“Our strategy on protecting intellectual property rights is key to the future success of this fascinating technology,” says Lone Schoett Kunoee, CEO of Consolidated Holdings A/S and Chairman of TOOsonix, in a news release. “We invested in TOOsonix from the very early phase as we saw a great potential in developing the technology into a broader range of applications as well as commercializing the product to a world market. Obtaining and developing patents and IPR are critical aspects of this journey, and we are convinced that this will secure strong commercial implementation.”